These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 31948539)

  • 1. [Promise of Neoadjuvant Immunotherapy in Resected Non-small Cell Lung Cancer].
    Yao S; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2020 Jan; 23(1):55-59. PubMed ID: 31948539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer.
    Jiang L; Huang J; Jiang S; Rong W; Shen Y; Li C; Tian Y; Ning J; Chen X; Yang Y; Ding Z; Li Z; Luo Q
    Cancer Immunol Immunother; 2021 Aug; 70(8):2313-2321. PubMed ID: 33512555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in patients with early stage resectable nonsmall cell lung cancer.
    Ghysen K; Vansteenkiste J
    Curr Opin Oncol; 2019 Jan; 31(1):13-17. PubMed ID: 30325753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant and Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer.
    Broderick SR
    Thorac Surg Clin; 2020 May; 30(2):215-220. PubMed ID: 32327180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Progress in Neoadjuvant Immunotherapies for Resectable Non-small Cell Lung Cancer].
    Wang S; Mao Y
    Zhongguo Fei Ai Za Zhi; 2020 May; 23(5):371-380. PubMed ID: 32283581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Progress of immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer].
    Chen XY; Yang F
    Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):872-877. PubMed ID: 31694138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological Aspects of Cryoablation of Non-Small Cell Lung Cancer: A Comprehensive Review.
    Katzman D; Wu S; Sterman DH
    J Thorac Oncol; 2018 May; 13(5):624-635. PubMed ID: 29391289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity.
    Predina JD; Haas AR; Martinez M; O'Brien S; Moon EK; Woodruff P; Stadanlick J; Corbett C; Frenzel-Sulyok L; Bryski MG; Eruslanov E; Deshpande C; Langer C; Aguilar LK; Guzik BW; Manzanera AG; Aguilar-Cordova E; Singhal S; Albelda SM
    Mol Ther; 2021 Feb; 29(2):658-670. PubMed ID: 33160076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy.
    Gentzler RD; Riley DO; Martin LW
    Curr Oncol Rep; 2020 Aug; 22(11):109. PubMed ID: 32803520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Pathologic Complete Response to Neoadjuvant Chemotherapy and Immunotherapy Followed by Surgery in a Patient With NSCLC.
    Ma X; Li B; Li Y; Lu L; Chen H
    J Thorac Oncol; 2019 May; 14(5):e104-e106. PubMed ID: 31027744
    [No Abstract]   [Full Text] [Related]  

  • 11. Cytokine immunotherapy of non-small cell lung cancer.
    Dubinett SM; Kradin RL
    Reg Immunol; 1993; 5(3-4):232-43. PubMed ID: 8240940
    [No Abstract]   [Full Text] [Related]  

  • 12. Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
    Ahern E; Solomon BJ; Hui R; Pavlakis N; O'Byrne K; Hughes BGM
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemo-immunotherapy modifies CD4(+)CD25(+) regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients.
    Pircher A; Gamerith G; Amann A; Reinold S; Popper H; Gächter A; Pall G; Wöll E; Jamnig H; Gastl G; Wolf AM; Hilbe W; Wolf D
    Lung Cancer; 2014 Jul; 85(1):81-7. PubMed ID: 24780112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?
    Rassy E; Mezquita L; Remon J; Besse B
    Immunotherapy; 2019 Sep; 11(13):1149-1160. PubMed ID: 31361172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Commentary: Neoadjuvant immunotherapy followed by lung cancer resection: Is the future already here?
    Reddy RM
    J Thorac Cardiovasc Surg; 2024 Jun; 167(6):1908-1909. PubMed ID: 37863180
    [No Abstract]   [Full Text] [Related]  

  • 16. Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer.
    Chuang JC; Liang Y; Wakelee HA
    Hematol Oncol Clin North Am; 2017 Feb; 31(1):31-44. PubMed ID: 27912832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy in non-small-cell lung cancer: from targeted molecules to resistance patterns.
    Brassart-Pasco S; Dalstein V; Brassart B; Dewolf M; Clavel C; Oudart JB
    Pharmacogenomics; 2020 Jul; 21(10):705-720. PubMed ID: 32567537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer.
    Conroy MR; Dennehy C; Forde PM
    Lung Cancer; 2023 Sep; 183():107314. PubMed ID: 37541935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immunotherapeutic landscape in non-small cell lung cancer and its surgical horizons.
    Rhodin KE; Rucker AJ; Ready NE; D'Amico TA; Antonia SJ
    J Thorac Cardiovasc Surg; 2020 Apr; 159(4):1616-1623. PubMed ID: 31836182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibition in early-stage non-small cell lung cancer.
    Cuppens K; Du Pont B; Knegjens J; Maes B; Baas P
    Lung Cancer; 2024 Jul; 193():107855. PubMed ID: 38896941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.